Compare Sana Biotechnology Inc (SANA) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wheaton Precious Metals Corp — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Wheaton Precious Metals Corp trades at $135 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 53.9× Sana Biotechnology Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WPM | |
|---|---|---|
Market Cap | $1.13B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $165.72 |
52-Week Low | $2.68 | $91.02 |
Enterprise Value | $1.05B | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Wheaton Precious Metals (WPM) trades at $135.00, up 1.21% on the day, with a bullish technical signal supported by moving averages. The company reported record first-half 2026 results, with Q2 earnings of $1.19 per share beating estimates, driven by higher metal prices and sales volumes. Strong profitability is evident with a net income margin of 64.66% and robust cash flow from operations of $1.90 billion in 2025. Analyst consensus is strongly positive with a buy rating from 80% of covering firms and a price target of $161.75.
The outlook remains favorable given sustained high precious metal prices and operational execution, though elevated valuation multiples and potential commodity price volatility present risks. Upside is supported by consistent earnings beats and institutional confidence, but investors should weigh the stock's premium pricing against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
